Hearing loss is a major health and economic burden on society. T e World Health Organization estimates that over 5% of the world's population-360 million peoplesuf er from a disabling hearing loss (1) . Hearing impairment can result in communication disorders, leading to educational, social, and vocational ramif cations that can adversely af ect quality of life. Hearing loss is also associated with dementia in the elderly. Sensorineural hearing loss is the most common form of deafness and typically occurs af er the degeneration of cochlear hair cells that normally convert acoustic vibrations into nerve impulses within the primary cochlear af erents known as spiral ganglion neurons (SGNs) (Fig. 1, A 
and B).
Patients with a severe-to-profound sensorineural hearing loss receive no benef t from amplif cation via a conventional hearing aid because of an absence of hair cells; the only therapeutic intervention available to these patients is a cochlear implant, or "bionic ear. " Now, Pinyon and colleagues of er the possibility of improved "bionic hearing" by modifying a cochlear implant to assist in gene therapy (2) .
THE BIONIC EAR
Cochlear implants electrically stimulate SGNs in order to convey the spectral and temporal cues of speech. T ese devices contain an array of up to 22 platinum electrodes that are inserted into the scala tympani-a f uid-f lled canal within the cochlea-to electrically stimulate discrete populations of SGNs. Cochlear implants take advantage of the tonotopic organization of the SGNs; stimulation of electrodes in the apex of the cochlea evokes low-pitch sensations, while stimulation of electrodes positioned more basally evoke higher pitches. Implanted in more than 300,000 patients around the world, cochlear implants are one of the most successful bionic devices developed; they are ef ective across the broad range of etiologies associated with deafness and can be used in both adults and children.
Although cochlear implant recipients typically receive substantial benef t in speech understanding in quiet settings, bionic ear performance decreases in noisy environments. In addition, these devices do not convey the rich aural texture of music or tonal languages very well. A major reason for this reduced performance is the limited number of independent stimulation channels available owing to extensive current spread in the highly conductive, f uid-f lled cochlea. T is produces far broader neural activation of SGNs than does natural hearing, leading to a reduction in the f delity of neural input to the auditory system. T ere are several approaches designed to improve the selectivity of electrical stimulation within the cochlea, including the use of currentfocusing techniques to create more localized electrical f elds and the use of drug-based therapies to improve the electrode-neural interface. For example, applying exogenous neurotrophins to the cochlea promotes SGN neurite growth toward the electrode array (3), resulting in reduced thresholds to electrical stimulation.
Pinyon et al. describe a new technique to deliver neurotrophins into the deaf cochlea using "close-f eld" electroporation (CFE) gene therapy (2) . Electroporation is a means of transferring gene constructs into cells by increasing the permeability of the cell membrane through a series of brief but intense electric pulses. In this way, the authors were able to transduce mesenchymal cells lining the scala tympani of the cochlea with a complementary DNA (cDNA) gene construct designed to drive the expression of brain-derived neurotrophic factor (BDNF) (Fig. 1C) . T e authors adapted a commercially available cochlear implant electrode array to generate the localized high electric f eld necessary to achieve the electroporation-mediated gene delivery. T ey f rst evaluated the feasibility of the approach and optimized the electroporation parameters ex vivo in order to conf rm that BDNF is delivered to the mesenchymal cells proximal to the electrode array.
Once proof of concept was demonstrated, the CFE approach was evaluated in vivo by using normal-hearing guinea pigs to again demonstrate the selective transduction of mesenchymal cells. T e guinea pig cochlea has many anatomical features in common with the human inner ear and is widely used as an animal model of human disease in auditory research. Last, the experiment was repeated in deafened animals that were chronically implanted with an electrode array af er electroporation (Fig.  1C) . T e electrode array was activated 2 weeks af er gene delivery, and the electrically evoked auditory brainstem response was recorded to monitor the functional status of the SGNs. Importantly, the mean electrical threshold of the BDNF treatment group was signif cantly lower than that of the control cohort, demonstrating an important functional advantage that has also been reported in the use of pump-based BDNF delivery techniques in animals (4-6). T e observed functional advantage was consistent with the anatomical f ndings that show a signif cant increase in both SGN soma area and ectopic neurite outgrowth toward the electrode array in the BDNF group af er a 2-week treatment period.
Taken together, these data show that the technique can result in an improved electrode-neural interface in deafened cochleae. It is anticipated that an improved interface will contribute to improved selectivity of electrical stimulation associated with cochlear implants. Greater selectivity of neural stimulation is expected to increase the f delity of neural input to the auditory system, resulting in improved hearing outcomes.
CAN YOU HEAR ME NOW?
Hair cells are sensitive to many forms of pathology, including hereditary disorders, ototoxic chemicals, infections, noise exposure, and aging. Hair cells do not regenerate in mammals, and their loss initiates a sequence of pathological changes in SGNs that includes the retraction of spiral ganglion neurites from the organ of Corti (Fig. 1B) 
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target neurons for cochlear implants; therefore, the degeneration of their peripheral neurites, or loss of the neuron itself, reduces the ef cacy of the electrode-neural interface as the neuron retracts from the electrode array within the scala tympani (Fig. 1B) . Over the past decade, researchers have been exploring safe and ef ective ways of delivering exogenous neurotrophins to the deafened cochlea with the specif c objective of improving the electrode-neural interface. T e study by Pinyon et al. (2) is an important contribution to this work.
Although the inner ear has been a target for drug-based therapies for over 60 years via systemic or middle-ear routes, direct application to the cochlea has only been recently used clinically and is restricted to patients with a moderate to severe hearing loss in which the risk of further damage to their hearing is reduced. T ese delivery techniques are usually designed to be performed in association with cochlear implantation because the scala tympani is already surgically exposed for the implantation of the electrode array. Techniques evaluated to date in preclinical studies include drug elution from an electrode array carrier; drug release from a reservoir and cannula within the electrode array; viral-mediated gene therapy; cell-based therapies; and nanotechnology-inspired release, either as a polymer coating on the electrode array or via slow release particles that are inserted into the cochlea just before or af er the insertion of the electrode array (7) (8) (9) . Although several of these techniques have demonstrated SGN rescue and functional evidence of an improved electrode-neural interface, some also bring potential clinical complications, such as the risk of infection associated with a drug reservoir and cannula system. Clinical trials (not involving the delivery of neurotrophins) are about to commence using drug elution from an electrode array and viral-mediated gene delivery techniques.
NEURONAL RESCUE
Pinyon et al. demonstrated both neurite growth into the scala tympani in the proximity of the electrode array and improved bionic hearing in the form of reduced electrical thresholds, using a technique and device that are transferrable to the clinic. However, several important questions still remain. First, the long-term ef cacy of the approach is unknown. T e authors demonstrated neurite regrowth and functional advantage in the f rst 2 weeks af er the treat- FOCUS ment but described a reduction in BDNF expression over the 3 to 6 weeks af er the gene delivery period. A key question associated with the ef cacy of this technique is the duration of any functional advantage af er loss of the neurotrophin expression. To this end, there is evidence that chronic depolarization of SGNs potentiates the rescue ef ects of exogenous neurotrophins (6); therefore, the long-term ef cacy of this technique needs to be evaluated in concert with chronic electrical stimulation via a cochlear implant.
In addition, the longevity of mesenchymal cells that take up the plasmid is unknown, as is their status af er a long-term hearing loss. Studies to evaluate the turnover of these cells in experimental animals and their status in human cochleae are necessary. Furthermore, techniques designed to improve the longevity of BDNF expression and methods that allow targeting of other cells within the cochlea also need to be explored.
T is new work describes ectopic sprouting of SGN neurites in response to the BDNF treatment. T is is a common f nding associated with exogenous delivery of neurotrophins that has raised concerns about the maintenance of the cochlea's tonotopic organization. Although evidence to date indicates that this organization is not adversely af ected (10), additional long-term experiments are warranted.
Last, in the study by Pinyon et al., the stimulus parameters that delivered optimal gene delivery were well beyond the specif cations of a modern cochlear implant. To translate this technology to the clinic, stimulus parameters for safe and ef ective electroporation need to be explored within the constraints of the specif cations of the cochlear implant stimulator.
T ese questions aside, this new work presents a novel gene delivery technique to regenerate SGN neurites and improve hearing outcomes for cochlear implant users. T e method is readily translatable to the clinic, requiring only a minor modif cation in surgical procedure-the delivery of a small volume of plasmid to the cochlea followed by a brief period of stimulation to drive the gene transfer. One exciting outcome is the potential to apply the technique to other medical bionics applications, such as retinal prostheses and deep brain stimulation. Like cochlear implants, these devices electrically stimulate damaged nerves. T erefore, the safe and local application of therapeutic genes or drugs delivered via electroporation could improve the clinical outcomes for patients using a wide variety of prosthetic devices.
